In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp
- 28 February 2003
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 45 (2), 131-135
- https://doi.org/10.1016/s0732-8893(02)00507-2
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- In Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium IsolatesAntimicrobial Agents and Chemotherapy, 2001
- Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin BJournal of Antimicrobial Chemotherapy, 2000
- Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.Journal of Antimicrobial Chemotherapy, 2000
- In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patientsJournal of Antimicrobial Chemotherapy, 1999
- In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin BDiagnostic Microbiology and Infectious Disease, 1999
- Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatusJournal of Antimicrobial Chemotherapy, 1998
- Invasive AspergillosisClinical Infectious Diseases, 1998
- In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important moldsAntimicrobial Agents and Chemotherapy, 1997
- Therapeutic Outcome in Invasive AspergillosisClinical Infectious Diseases, 1996